Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach (UKPDS 87) by Agbaje, Olorunsola F. et al.
                                                                    
University of Dundee
Predicting post one-year durability of glucose-lowering monotherapies in patients with
newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine
approach (UKPDS 87)
Agbaje, Olorunsola F.; Coleman, Ruth L.; Hattersley, Andrew T.; Jones, Angus G.; Pearson,
Ewan R.; Shields, Beverley M.
Published in:









Link to publication in Discovery Research Portal
Citation for published version (APA):
Agbaje, O. F., Coleman, R. L., Hattersley, A. T., Jones, A. G., Pearson, E. R., Shields, B. M., Holman, R. R., &
MASTERMIND consortium (2020). Predicting post one-year durability of glucose-lowering monotherapies in
patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach
(UKPDS 87). Diabetes Research and Clinical Practice, 166, [108333].
https://doi.org/10.1016/j.diabres.2020.108333
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 08. Dec. 2021
Journal Pre-proofs
Predicting Post One-year Durability of Glucose-lowering Monotherapies in
Patients with Newly-diagnosed Type 2 Diabetes Mellitus – A MASTER-
MIND Precision Medicine Approach (UKPDS NN <number to be added on
acceptance >)
Olorunsola F. Agbaje, Ruth L. Coleman, Andrew T. Hattersley, Angus G.





To appear in: Diabetes Research and Clinical Practice
Received Date: 14 April 2020
Revised Date: 27 June 2020
Accepted Date: 13 July 2020
Please cite this article as: O.F. Agbaje, R.L. Coleman, A.T. Hattersley, A.G. Jones, E.R. Pearson, B.M. Shields, 
R.R. Holman, for the MASTERMIND consortium, Predicting Post One-year Durability of Glucose-lowering 
Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus – A MASTERMIND Precision 
Medicine Approach (UKPDS NN <number to be added on acceptance >), Diabetes Research and Clinical 
Practice (2020), doi: https://doi.org/10.1016/j.diabres.2020.108333
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover 
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version 
will undergo additional copyediting, typesetting and review before it is published in its final form, but we are 
providing this version to give early visibility of the article. Please note that, during the production process, errors 
may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2020 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/
Page 1 of 20
Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients 
with Newly-diagnosed Type 2 Diabetes Mellitus – A MASTERMIND Precision Medicine 
Approach (UKPDS NN <number to be added on acceptance >)
Olorunsola F. Agbaje,1 Ruth L. Coleman,1 Andrew T. Hattersley,2 Angus G. Jones,2 
Ewan R. Pearson,3 Beverley M. Shields,2 and Rury R. Holman,1 
for the MASTERMIND consortium
1 Diabetes Trials Unit–University of Oxford–Oxford–U.K.
2 Institute of Biomedical & Clinical Science–University of Exeter Medical School–Exeter–U.K. 








Tel: +44 (0) 1865 857116 
Page 2 of 20
Abstract
Aims Predicting likely durability of glucose-lowering therapies for people with type 2 
diabetes (T2D) could help inform individualised therapeutic choices.
Methods We used data from UKPDS patients with newly-diagnosed T2D randomised to 
first-line glucose-lowering monotherapy with chlorpropamide–glibenclamide–basal insulin or 
metformin. In 2,339 participants who achieved one-year HbA1c values <7.5% (<59 
mmol/mol)–we assessed relationships between one-year characteristics and time to 
monotherapy-failure (HbA1c ≥7.5% or requiring second-line therapy). Model validation was 
performed using bootstrap sampling.
Results Follow-up was median (IQR) 11.0 (8.0–14.0) years. Monotherapy-failure occurred 
in 72%–82%–75% and 79% for those randomised to chlorpropamide–glibenclamide–basal 
insulin or metformin respectively–after median 4.5 (3.0–6.6)–3.7 (2.6–5.6)–4.2 (2.7–6.5) and 
3.8 (2.6– 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA1c and BMI 
values–with other risk factors varying by type of monotherapy–with predictions to within ±2.5 
years for 55%–60%–56% and 57% of the chlorpropamide–glibenclamide–basal insulin and 
metformin monotherapy cohorts respectively.
Conclusions Post one-year glycaemic durability can be predicted robustly in individuals 
with newly-diagnosed T2D who achieve HbA1c values <7.5% one year after commencing 
traditional monotherapies. Such information could be used to help guide glycaemic 
management for individual patients.
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Introduction
The ADA/EASD Position Statement for the management of hyperglycaemia in type 2 diabetes 
(T2D) recommends a patient-centred approach to identifying the most appropriate glucose-
lowering therapy for a given individual.[1] However–no specific guidance is provided as to how 
best to select the most durable glycaemic agent for any one individual. One strategy which 
could help make the most effective use of available glucose-lowering therapies is to target 
treatment to those who are most likely to respond to therapy–an approach known as stratified–
or precision medicine.[2]
At a population level–mean HbA1c levels in people with newly-diagnosed T2D 
decrease initially with therapy and then rise over time–necessitating multiple glucose-lowering 
therapies.[3] This biphasic pattern is sometimes referred to as the “Nike Curve” as it resembles 
the Nike "swoosh" trademark. While substantial research has been published investigating 
potential predictors of initial response to glucose lowering therapy–whether durability of 
individual therapies varies by participant characteristics and can be predicted has not been 
previously investigated. The MRC/APBI funded STratification and Extreme Response 
Mechanism IN Diabetes (MASTERMIND) consortium felt that the biphasic glucose curve in 
T2D would best be modelled by addressing the initial glycaemic drop with therapy and then–
separately–its subsequent rise. This paper examines the development of models that predict 
the rise in glucose values during the second upward phase–taking into account the first-year 
response. Individual patient upward HbA1c trajectories  are difficult to predict given their often 
apparently random variation–although a DIRECT study of the clinical and genetic 
determinants of glycaemic progression in patients with T2D suggested that increased 
triglyceride and low HDL-cholesterol levels were independently associated with an increased 
rate of progression of diabetes.[4] In clinical practice, however, it remains unclear at an 
individual patient level which factors most affect durability of glycaemic response to glucose-
lowering therapies.  
Potential predictors were investigated for the post one-year glycaemic durability of the 
glucose-lowering monotherapies allocated at random as first-line therapy to patients with 
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newly-diagnosed T2D enrolled into the UK Prospective Diabetes Study (UKPDS).[5] UKPDS 
participants were assigned at random to monotherapy with chlorpropamide, glibenclamide, 
basal insulin or metformin (only if >120% ideal body weight). In those who achieved 
acceptable HbA1c values at one year, we sought to predict the time at which their glycaemic 
control would worsen to the point when the addition of second-line glucose-lowering therapy 
would likely be indicated by many guidelines. 
Subjects
We used data from UKPDS patients. Details of UKPDS recruitment, inclusion and exclusion 
criteria, protocol and trial results have been published.[5-7] Briefly, patients with newly-
diagnosed T2D who were allocated to the UKPDS intensive glucose control arm were 
randomised to first-line glucose-lowering monotherapy with chlorpropamide (a first-generation 
sulfonylurea), glibenclamide (a second generation sulfonylurea), basal insulin or metformin 
(only if >120% ideal body weight). The aim of the intensive glucose control arm was to achieve 
and maintain fasting plasma glucose (FPG) levels <6.0 mmol/l by increasing monotherapy 
doses as necessary to the maximum permitted or tolerated, based on 3-monthly FPG 
measurements. Glycaemic rescue, with the addition of a second protocol-specified glucose-
lowering agent, was only permitted if repeated FPG values were >15.0 mmol/l or if 
hyperglycaemic symptoms had become unacceptable. The participants selected for this study 
were those at one-year who remained on their allocated monotherapy, had an HbA1c <7.5% 
(<59 mmol/mol) at 1 year, and who had the requisite analytic data available.
Materials and Methods
For the purposes of this analysis monotherapy failure, i.e. the need for a second line glucose-
lowering therapy, was defined as an HbA1c ≥7.5% (≥59 mmol/mol) or the UKPDS protocol-
driven requirement for glycaemic rescue. Post one-year time-to-monotherapy-failure times 
were calculated as the interval between the one-year visit and the time when either of the 
indications for monotherapy failure were met. As HbA1c values were only measured 
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annually,[5] we used linear interpolation to estimate time points between visits when values 
likely became ≥7.5% (≥59 mmol/mol).
The two outcomes of interest for each monotherapy were: 1) The median post one-
year time-to-monotherapy-failure; 2) The degree to which this time point could be predicted 
from the one-year demographic, phenotypic and laboratory data available. We developed a 
BASIC model using only those variables likely to be available in routine clinical practice, i.e. 
HbA1c, age, sex, ethnicity, smoking, body mass index (BMI), plasma creatinine, total 
cholesterol, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), plasma triglycerides and 
estimated glomerular filtration rate (eGFR), and an EXTENDED model that included additional 
variables collected as part of the UKPDS protocol, i.e. fasting plasma glucose (FPG), fasting 
plasma insulin (FPI), HOMA2_%B, HOMA2_%S and urinary creatinine.
Statistical Analysis
Complete case (CC) and multiple-imputed complete data (MICD) datasets were used to 
construct the BASIC and the EXTENDED models, with missing data imputed by multiple 
imputation function in R (aregImpute). The mechanisms and patterns of missing data were 
investigated by employing further R functions (naclus and naplot) for a cluster analysis 
investigating missing values status and graphical representation of missing patterns. CC and 
MICD datasets from each monotherapy cohort were used to develop models and validated 
using a bootstrapping procedure. MICD sensitivity analyses were used to check that any 
missing data did not bias complete case model estimates. HOMA2_%B and HOMA2_%S 
values were derived from FPG and FPI levels using the HOMA2 Calculator,[8] and eGFR 
values were calculated using the Modification of Diet in Renal Disease (MDRD) formula.[9] 
Univariate accelerated failure time (AFT) regression modelling was used to investigate 
the relationship between variables measured at one year and the subsequent time-to-
monotherapy-failure, based on a log-logistic three-parameter distribution.  We optimised 
potential associations by examining alternative distributions, e.g. log, square, square root, etc., 
and the best fit with the simplest form for clinical interpretation chosen. A statistical significance 
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level of p≤0.1 was used in univariate AFT regression analyses to select which variables would 
be included in multivariate AFT regression analyses. 
A multivariable AFT regression was performed in separate prognostic models for each 
monotherapy cohort to assess independent associations between one-year covariates and 
subsequent time-to-monotherapy-failure. The final model variables were decided by backward 
selection procedures during which individual model outputs (regression coefficients, p-values, 
Akaike information criterion (AIC), Bayesian information criterion (BIC), and log likelihood 
value were monitored. All models were validated internally for their discrimination and 
predictive abilities using bootstrap sampling. In addition, the relative performance of the basic 
and extended models was evaluated by comparing their estimated information criteria (AIC 
and BIC).
All statistical analyses were performed with Regression Modelling Strategies (RMS) 
Package (Version 5.0-0, 2016-10-31), R-3.4.3 for Windows (Copyright© 2015, The R 
Foundation for Statistical Computing) and STATA version 15.0 (StataCorp LP 4905 Lakeway 
Drive College Station, Texas 77845-4512 USA).
Results
Of the 5102 patients enrolled into the UKPDS, 2110 (41%) were included in the MICD dataset 
who fulfilled our criteria for this analysis and who had achieved an HbA1c <7.5% (<59 
mmol/mol) at one year. They had been assigned at random to chlorpropamide (N=573, 27%), 
glibenclamide (N=462, 22%), basal insulin (N=828, 39%) or metformin (N=247, 18%) with a 
median (IQR) post one-year follow-up of 11.0 (8.0, 14.0) years (Supplementary Appendix 
Fig. S1). There were too few patients allocated to glipizide (N=170) in UKPDS Glucose Study 
II[5] to be included in this analysis. Table 1 lists the one-year variables utilised, their summary 
statistics, the proportions of missing data and the modelling approaches used. There were no 
missing values for age, sex, race or smoking, whilst the proportions of missing data for total 
cholesterol, LDL-C, HDL-C, triglycerides, creatinine, fasting plasma glucose, insulin, eGFR, 
HOMA2_%B and HOMA2_%S ranged from 9% to 27%. 
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In the MICD data set, post one-year monotherapy-failure occurred in 76% (1607/2110) 
participants, comprising 72% (415/573) for chlorpropamide, 82% (378/462) for glibenclamide, 
75% (620/828) for basal insulin, and 79% (194/247) for metformin. The overall proportion of 
these participants requiring glycaemic rescue per protocol was 4.7% (99/2110), being 7.7% 
(44/573) for chlorpropamide, 9.7% (45/462) for glibenclamide, 0.2% (2/828) for basal insulin 
and 3.2% (8/247) for metformin.
The number of patients in the complete case data set was 1438 (82% of the MICD dataset) 
with the proportions randomised to each glucose-lowering monotherapy being 70% (399/573) 
for chlorpropamide, 67% (318/462) for glibenclamide, 67% (557/828) for basal insulin and 
66% (164/247) for metformin.
BASIC model predictors of time-to-monotherapy-failure using routinely available data
Overall, the median (IQR) time-to-monotherapy-failure was 4.0 (2.0, 8.0) years. This time 
differed by monotherapy being 4.5 (3.0, 6.6) years for chlorpropamide, 3.7 (2.6, 5.6) years for 
glibenclamide, 4.2 (2.7, 6.) years for basal insulin and 3.8 (2.6, 5.2) years for metformin. In 
univariate analyses, time-to-monotherapy-failure increased with higher age, lower BMI, male 
sex and being White Caucasian. (Supplementary Appendix Table S1). 
In the CC multivariate BASIC model, one-year HbA1c and BMI were predictive factors 
for all monotherapies, with higher values associated with a shorter time-to-monotherapy-
failure (Table 2). Additional factors by monotherapy cohort were: chlorpropamide (age, sex, 
ethnicity, smoking, LDL-C and triglycerides; glibenclamide (age and triglycerides); basal 
insulin (age, total cholesterol and HDL-C); metformin (none). The magnitude and direction of 
the different effect sizes are listed in Table 2 as failure time ratios with 95% confidence limits. 
The findings for the equivalent BASIC MICD multivariate model analyses were all similar 
(Supplementary Appendix Table S2).
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EXTENDED model predictors of time-to-monotherapy-failure
The median time-to-monotherapy-failure predicted by the extended model with additional 
variables for each monotherapy cohort was 4.7 (3.0, 6.9) years for chlorpropamide, 4.0 (2.6, 
6.0) years for glibenclamide, 3.9 (2.6, 6.1) years for insulin, and 3.8 (2.6, 5.2) years for 
metformin. (Table 2). 
In the CC multivariate EXTENDED model, one-year HbA1c and BMI were predictive factors for 
all monotherapies, with higher values of both associated with a shorter time-to-monotherapy-
failure. Additional factors by monotherapy cohort were: chlorpropamide (age, ethnicity, 
smoking, LDL-C, FPG and HOMA2_%B); glibenclamide (age, ethnicity and FPG); basal 
insulin (age, smoking, FPI, HOMA2_%B and HOMA2_%S); metformin (none).  The magnitude 
and direction of the different effect sizes are listed in Table 2. The findings for the equivalent 
EXTENDED model MICD analyses were all similar (Supplementary Appendix Table S2).
The results of the internal validation, the discrimination and calibration bootstrap 
corrected indices (Nagelkerke R2, Somers’ D[Dxy], and shrinkage factor [Slope]) are shown in 
Table 2. The discrimination indices, R2 and Dxy, range from 15.0%–29.3% and 0.3058-0.4062 
across cohorts and models, respectively. The bootstrap corrected slopes were greater than 
90% across cohorts and models. Similar results were obtained for the MICD models 
(Supplementary Appendix Table S2).
The smaller AIC and BIC values for the extended models show that they fit the data better for 
all the monotherapies than the basic models, except for metformin. 
    
Predictive equations
The predictive equations for individual patient time-to-monotherapy-failure derived from the 
BASIC and EXTENDED models are shown in Supplementary Appendix Figures S2 and S3 
respectively. The performance of these equations for the BASIC and EXTENDED models are 
depicted in Fig. 1 and Supplementary Appendix Fig. S4, comparing the differences between 
predicted and observed time-to-monotherapy-failure with the observed time-to-monotherapy-
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failure for each monotherapy cohort. For the BASIC model, the post one-year time-to-
monotherapy-failure was predictable to within ±2.5 years for 55%, 60%, 56% and 57% of 
individuals allocated to chlorpropamide, glibenclamide, basal insulin and metformin 
monotherapy respectively. The corresponding proportions for the EXTENDED model were 
56%, 61%, 59% and 57% respectively.
Median time-to-monotherapy-failure predictions, calculated for each monotherapy for 
five example patients using the BASIC model, are illustrated in Table 3, showing a different 
rank order for monotherapy durability depending on patient’s one-year characteristics. The 
equivalent predictions for the EXTENDED models are shown in Supplementary Appendix 
Fig. S5.
Discussion
These analyses show that the post one-year durability of glycaemic control for the majority of 
individuals with newly-diagnosed T2D who have an HbA1c <7.5% one year after commencing 
treatment with chlorpropamide, glibenclamide, basal insulin or metformin monotherapies, can 
be estimated to within ±2.5 years for around half of the patients in each monotherapy cohort. 
Application of the predictive equations showed that a hierarchy of glycaemic durability can be 
derived using routinely available clinical information. Such information could be used in the 
management of tyT2D to help guide therapeutic choices for individual patients.
It is of interest that for most of the monotherapies studied it is largely the same factors 
that predict glycaemic durability, with a lower one-year HbA1c, lower one-year BMI and higher 
age of diabetes diagnosis onset favouring greater durability.  This fits with the previous paper 
by Zhou et al [4] that showed higher BMI, HbA1c and a younger age of diagnosis were 
associated with more rapid progression to insulin.  A key finding of our study is that these 
factors have a different quantitative impact on different therapies explaining why there is 
overall a difference in durability between therapies.  Previous studies have compared 
glycaemic durability with different agents [11] but have not examined the factors which are 
predictive for individuals.  
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The strengths of these analyses include the randomised allocation of therapies from 
diagnosis of T2D and the unusually long follow-up period as a consequence of the UKPDS 
protocol requirement for glycaemic rescue only when FPG values became >15.0 mmol/l or 
hyperglycaemic symptoms became unacceptable. Limitations include the lack of data for other 
indicators possibly related to the modes of action of the therapies examined, e.g. fasting and 
postprandial C-peptide levels which were not collected in the UKPDS, as well as the relatively 
small sample sizes. The proportions of missing data could also be a concern but these were 
either missing completely at random, or missing at random, with the MICD sensitivity analyses 
showing no evidence of missing data biasing the results. The two sulfonylureas 
(chlorpropamide and glibenclamide) analysed here are no longer recommended in routine 
clinical practice but the methodology we have used could be applied to more 
contemporaneous datasets to estimate the likely durability of newer glucose-lowering agents.
Routinely available phenotypic and laboratory data in people with newly-diagnosed T2D, 
who have achieved an HbA1c <7.5% (<59 mmol/mol) on monotherapy with chlorpropamide, 
glibenclamide, basal insulin or metformin at one year after diagnosis, can be used to estimate 
the likely glycaemic durability of continued monotherapy. Such information could be used to 
help guide individualised patient management. 
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Figure Legend
Fig. 1. Comparison of the differences between the complete case basic model predicted and 
the observed time-to-monotherapy-failure (observed minus predicted), with the observed 
time-to-monotherapy-failure. Panel A: Chlorpropamide, Panel B: Glibenclamide, Panel C: 
Basal insulin, Panel D: Metformin. The dotted horizontal lines depict ±2.5 years.
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Table 1. Variables included in the basic and extended models.
Number with missing data n (%)
Summary Chlorpropamide Glibenclamide Insulin Metformin Modelling
 Variable statistics* [573] [462] [828] [247] methodology
HbA1c (%) 5.9 (0.8) 573 (0%) 462 (0%) 828 (0%) 247 (0%) Linear
Age (years) 54 (47.859.7) 573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical
Sex 573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical
Male 1128 (61.3%)
Female 712 (38.7%)
Ethnicity 573 (0%) 462 (0%) 828 (0%) 247 (0%) Categorical
 Caucasian 1554 (84.5%)
Non-Caucasian 286 (15.5%)




BMI (kg/m2) 27.3 (24.7–30.8) 521 (9%) 409 (11%) 751 (9%) 214 (13%) Logarithm
Plasma creatinine (μmol/L) 83.8 (17.2) 444 (23%) 370 (20%) 645 (22%) 189 (23%) Linear
Total cholesterol (mmol/L) 5.4 (1.1) 439 (23%) 353 (24%) 632 (24%) 179 (28%) Linear
LDL-cholesterol (mmol/L) 3.5 (1) 433 (24%) 347 (25%) 616 (26%) 175 (29%) Linear
HDL-cholesterol (mmol/L) 1.1 (0.3) 434 (24%) 350 (24%) 623 (25%) 176 (29%) Linear
Plasma triglycerides (mmol/L) 1.5 (1.1–2.1) 436 (24%) 345 (25%) 624 (25%) 181 (27%) Logarithm
eGFR (ml/min/1.73m2) 79.5 (18.1) 444 (23%) 370 (20%) 645 (22%) 189 (23%) Linear
Extended Model
(additional variables)
Fasting plasma glucose (mmol/l) 6.8 (1.5) 516 (10%) 407 (12%) 747 (10%) 212 (14%) Linear
Fasting plasma insulin (mu/l) 13.9 (9.6–19.6) 440 (23%) 355 (23%) 618 (25%) 183 (26%) Logarithm
HOMA2_%B 80.9 (57.8–112.3) 430 (25%) 349 (24%) 601 (27%) 180 (27%) Logarithm
HOMA2_%S 53.5 (37.8–76.2) 430 (25%) 349 (24%) 601 (27%) 180 (27%) Logarithm
Urinary creatinine (µmol/l) 10.3 (5.9) 447 (22%) 365 (21%) 640 (23%) 189 (23%) Linear
*Summary statistics are mean (SD) or median (IQR) for continuous variables, and number (%) for categorical variables
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Table 2. Complete case (CC) multivariate analyses showing monotherapy failure time ratios and 95% confidence intervals.
Chlorpropamide Glibenclamide Insulin Metformin
Basic Model Variables TR [95% CI] P-Value TR [95% CI] P-Value TR [95% CI]
P-
Value TR [95% CI]
P-
Value
HbA1c (%) 0.65 [0.57–0.74] 0.000 0.56 [0.49–0.65] 0.000 0.54 [0.48–0.61] 0.000 0.56 [0.46–0.69] 0.000
Age (years)
<40  1 1 1 1
40-44  1.32 [0.82–2.14] 0.256 1.45 [0.76–2.77] 0.254 1.17 [0.71–1.93] 0.536 - -
45-49  1.39 [0.88–2.20] 0.160 1.58 [0.86–2.88] 0.139 1.10 [0.70–1.72] 0.694 - -
50-54  1.68 [1.12–2.52] 0.012 1.89 [1.05–3.40] 0.035 1.56 [1.00–2.42] 0.049 - -
55-59  1.60 [1.07–2.40] 0.023 2.06 [1.15–3.69] 0.015 1.81 [1.16–2.82] 0.009 - -
60-64  1.95 [1.30–2.91] 0.001 2.14 [1.21–3.80] 0.009 1.99 [1.27–3.11] 0.003 - -
>64  2.02 [1.15–3.53] 0.014 2.31 [1.15–4.66] 0.019 1.82 [1.09–3.05] 0.022 - -
Sex 
Male  1 1 1 1
Female  1.18 [0.95–1.48] 0.136 - - - - - -
Race 
Caucasian  1 1 1 1
Non-Caucasian  0.71 [0.53–0.94] 0.016 - - - - - -
Smoking 
Non-Smoker  1 1 1 1
Ex-Smoker  1.36 [1.04–1.79] 0.027 - - - - - -
Smoker  0.97 [0.75–1.26] 0.838 - - - - - -
Log BMI (kg/m2) 0.27 [0.15–0.49] 0.000 0.24 [0.12–0.46] 0.000 0.37 [0.22–0.62] 0.000 0.31 [0.11–0.93] 0.037
Plasma creatinine (μmol/L) - - - - - - - -
Total cholesterol (mmol/L) - - - - 0.93 [0.86–1.02] 0.112 - -
LDL-C (mmol/L) 0.90 [0.81–1.01] 0.067 - - - - - -
HDL-C (mmol/L) - - - - 1.36 [0.96–1.92] 0.085 - -
Log Triglycerides (mmol/L) 0.80 [0.65–1.00] 0.047 0.86 [0.70–1.06] 0.169 - - - -
eGFR (ml/min/1.73m2) - - - - - - - -
Information criteria
          AIC 1068.193 894.8231 1564.809 573.8394
          BIC 1013.907 1022.962 1512.145 573.8394
Bootstrap internal validation corrected-
index
          R2 0.1983 0.2359 0.2019 0.1503
          Somers’ Dxy 0.3420 0.3655 0.3518 0.3058
          Calibration slope 0.9074 0.9377 0.9427 0.9948
Model estimated failure time
Median[IQR] 4.5 [3.0–6.6] 3.7 [2.6–5.6] 4.2 [2.7–6.5] 3.8 [2.6–5.2]
Extended Model Variables - - - - - - - -
HbA1c (%) 0.71 [0.62–0.81] 0.000 0.65 [0.58–0.74] 0.000 0.56 [0.50–0.63] 0.000 0.56 [0.46–0.69] 0.000
Age (years)
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<40  1 1 1 1
40-44  1.21 [0.76–1.91] 0.422 1.39 [0.80–2.42] 0.240 1.21 [0.75–1.95] 0.461 - -
45-49  1.31 [0.85–2.03] 0.218 1.62 [0.97–2.70] 0.063 1.18 [0.77–1.82] 0.533 - -
50-54  1.54 [1.04–2.26] 0.029 1.55 [0.94–2.55] 0.084 1.64 [1.08–2.51] 0.031 - -
55-59  1.54 [1.04–2.26] 0.031 1.62 [0.99–2.65] 0.053 1.82 [1.19–2.77] 0.010 - -
60-64  1.86 [1.26–2.74] 0.002 1.65 [1.02–2.68] 0.043 1.96 [1.28–3.01] 0.004 - -
>64  1.77 [1.04–3.03] 0.037 1.66 [0.93–2.99] 0.089 1.88 [1.15–3.07] 0.019 - -
Sex 
Male  1 1 1 1
Female  - - - - - - - -
Race 
Caucasian  1 1 1 1
Non-Caucasian  0.70 [0.54–0.92] 0.010 0.69 [0.53–0.89] 0.005 - - - -
Smoking 
Non-Smoker  1 1 1 1
Ex-Smoker  1.15 [0.90–1.47] 0.269 - - 0.91 [0.74–1.12] 0.399 - -
Smoker  0.84 [0.66–1.07] 0.151 - - 0.77 [0.63–0.95] 0.014 - -
Log-BMI (kg/m2) 0.26 [0.14–0.47] 0.000 0.26 [0.15–0.46] 0.000 0.41 [0.24–0.70] 0.001 0.31 [0.11–0.93] 0.037
Plasma creatinine (μmol/L) - - - - - - - -
Total cholesterol (mmol/L) - - - - - - - -
LDL-C (mmol/L) 0.92 [0.83–1.01] 0.088 - - - - - -
HDL-C (mmol/L) - - - - - - - -
Log Triglycerides (mmol/L) - - - - - - - -
eGFR (ml/min/1.73m2) - - - - - - - -
Fasting plasma glucose (mmol/l) 0.81 [0.74–0.88] 0.000 0.80 [0.75–0.86] 0.000
Log HOMA2_%B 0.79 [0.61–1.04] 0.093 - - 1.23 [1.01–1.50] 0.011 - -
Log HOMA2_%S - - - - 1.44 [1.17–1.77] 0.033 -
Urinary creatinine (µmol/l) - - - - - - -
Information criteria
          AIC 1133.0270 936.9738 1514.873 587.3033
          BIC 1078.3590 1071.0390 1576.360 587.3033
Bootstrap internal validation corrected-
index
          R2 0.2463 0.2931 0.2251 0.1503
          Somers’ Dxy 0.3640 0.4062 0.3675 0.3058
          Calibration slope 0.9273 0.9540 0.9434 0.9948
Model estimated failure time
Median[IQR] 4.7 [3.0–6.9] 4.0 [2.6–6.0] 3.9 [2.6–6.1] 3.8 [2.6–5.2]
R2 = Nagelkerke R2 Somers’ D = Dxy–Slope = shrinkage factor–AIC = Akaike information criterion–BIC = Bayesian information criterion
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Table 3. Median time-to-failure (durability) calculated using the basic model equations and shown in rank order for six examplar cases.
Case  1 Case  2 Case  3 Case  4 Case  5 Case 6
HbA1c (%) 5.0 5.5 6 6.5 7 7.5
Age (years) 65 60 55 50 45 40
BMI (kg/m2) 25.0 27.0 29.0 31.0 33.0 35.0
Sex Male Female Male Female Male Male
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Fig. 1
